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Summary
Smooth muscle cells (SMCs) modulate their pheno-
type between proliferative and differentiated states in
response to physiological and pathological cues. In-
sulin-like growth factor-I stimulates differentiation of
SMCs by activating phosphoinositide-3-kinase (PI3K)-
Akt signaling. Foxo forkhead transcription factors act
as downstream targets of Akt and are inactivated
through phosphorylation by Akt. We show that Foxo4
represses SMC differentiation by interacting with and
inhibiting the activity of myocardin, a transcriptional
coactivator of smooth muscle genes. PI3K/Akt signal-
ing promotes SMC differentiation, at least in part, by
stimulating nuclear export of Foxo4, thereby releas-
ing myocardin from its inhibitory influence. Accord-
ingly, reduction of Foxo4 expression in SMCs by
siRNA enhances myocardin activity and SMC differ-
entiation. We conclude that signal-dependent interac-
tion of Foxo4 with myocardin couples extracellular
signals with the transcriptional program for SMC dif-
ferentiation.
Introduction
Unlike skeletal and cardiac muscle cells, smooth mus-
cle cells (SMCs) do not terminally differentiate and can
transition between a quiescent, contractile phenotype
and a proliferative synthetic phenotype in response to
physiological and pathological stimuli (reviewed in Ow-
ens et al., 2004). This phenotypic plasticity of SMCs
is essential for vascular development and remodeling
during disease. In response to vascular injury, dif-
ferentiated SMCs are provoked to proliferate and dedif-
ferentiate, while at the same time they express con-
tractile proteins required for normal cardiovascular
homeostasis. Abnormal proliferation and migration of
SMCs contribute to the pathogenesis of atherosclerotic
lesions, restenosis following angioplasty, hypertension,
and leiomyosarcoma, a smooth muscle tumor (Ross,
1993). A number of signaling pathways, including the
phosphoinositide-3-kinase (PI3K)/Akt, extracellular sig-
nal-regulated kinase (ERK), and p38 mitogen-activated
protein kinase (MAPK), have been implicated in the
control of SMC phenotypes (Duan et al., 2000; Hayashi
et al., 1999; Wang et al., 2003a). However, much re-
mains to be learned about the transcriptional mecha-*Correspondence: zhi-ping.liu@utsouthwestern.edu (Z.-P.L.); eric.
olson@utsouthwestern.edu (E.N.O.)nisms that link these signaling pathways to the program
for SMC gene expression.
Vascular SMC differentiation and phenotypic modu-
lation are characterized by changes in expression of
genes encoding smooth muscle (SM)-specific con-
tractile proteins and extracellular matrix proteins. Fully
differentiated SMCs express the highest levels of SM
contractile proteins such as SM α-actin, SM22α, SM my-
osin light chain kinase (SM-MLCK), SM-myosin heavy
chain (SM-MHC), and SM-calponin, which are required
to fulfill their principal contractile function. Proliferating
SMCs, in contrast, express reduced levels of con-
tractile proteins and higher levels of extracellular matrix
proteins. Consequently, changes of SM contractile
gene expression are often used to mark SMC pheno-
types (Owens et al., 2004).
Expression of SMC contractile genes depends on
a cis-acting DNA sequence known as a CArG box
(CC(A/T)6GG), which serves as the binding site for se-
rum response factor (SRF), a MADS (MCM1, Agamous,
Deficiens, SRF) box transcription factor (reviewed in
Miano, 2003). Depending on intracellular signals and
cell type, proteins containing the MADS domain are ca-
pable of activating or repressing distinct sets of genes
through combinatorial association with accessory fac-
tors. Earlier work from our laboratory and others showed
that myocardin is a potent coactivator of SRF that can
activate the program of SM differentiation in trans-
fected fibroblasts (for references, see Wang and Olson,
2004). Mice homozygous for a myocardin null allele die
during midgestation from an absence of differentiated
vascular smooth muscle cells (Li et al., 2003). Thus, my-
ocardin is sufficient and necessary for activation of SM
contractile protein genes and is therefore a likely target
for the signaling pathways that modulate SMC pheno-
types.
The PI3K/Akt signaling pathway has been shown to
stimulate SMC differentiation (Hayashi et al., 1998,
1999; Wang et al., 2003a). Foxo transcription factors
are downstream targets of Akt (reviewed in Van Der
Heide et al., 2004). Four mammalian Foxo proteins have
been described to date: Foxo1, Foxo3a, Foxo4, and
Foxo6 (Biggs et al., 2001; Van Der Heide et al., 2004).
Foxo proteins are expressed ubiquitously, with Foxo4
being expressed most abundantly in myocyte-contain-
ing tissues (Furuyama et al., 2000; Biggs et al., 2001).
The molecular mechanisms associated with regulation
of Foxo proteins in response to cytokines and growth
factors via the PI3K-Akt signaling pathway have been
well characterized (reviewed in Van Der Heide et al.,
2004). Phosphorylation of Foxo proteins, possibly by
Akt, at three key residues that are conserved within the
Foxo subfamily leads to their nuclear exclusion and in-
hibition of Foxo activities. In addition, it has been found
that Foxo3a undergoes Akt-independent phosphoryla-
tion by IκB kinase (Hu et al., 2004). In the absence of
PI3K-Akt signaling, Foxo proteins localize to the nu-
clear compartment, where they activate downstream
target genes to elicit various cellular responses. How-
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modulation of SMCs remains elusive.
Here we investigate the effect of Foxo4 on pheno-
typic modulation of vascular SMCs. We show that
Foxo4 interacts with myocardin and inhibits SM con-
tractile gene expression. The PI3K/Akt pathway medi-
ates the promyogenic effects of IGF-I on SMC pheno-
types, at least in part, by promoting the signal-dependent
dissociation of Foxo4 from myocardin. Consistent with
this notion, we show that nuclear Foxo4 expression is
upregulated in proliferating SMCs from the vascular
neointima of the carotid artery following injury in vivo,
a potent stimulus for phenotypic modulation of SMCs.
The signal-dependent interaction of Foxo4 with myo-
cardin provides a mechanism for coupling specific ex-
tracellular signals to the transcriptional program for
SMC differentiation.
Results
The PI3K/Akt Signaling Pathway Promotes SMC
Differentiation through Inactivation of Foxo4
Activation of the PI3K/Akt pathway by IGF-I promotes
SMC differentiation through an as yet undefined mech- F
anism (Hayashi et al., 1998). Since Foxo proteins are I
downstream targets of PI3K/Akt signaling, and Foxo4 (
ais the most abundant family member in myocyte-con-
ttaining tissues (Furuyama et al., 2000), we hypothe-
asized that it might act in the signaling pathway whereby
L
IGF-I modulates SMC differentiation. To test this hy- a
pothesis, we first investigated whether the Foxo4 pro- (
tein undergoes nuclear export in response to IGF-I sig- e
tnaling in SMCs. As shown in Figure 1A, a GFP-Foxo4
Iprotein was localized to the nuclei of the rat aortic SMC
dline A7r5 in serum-free medium. Addition of IGF-I re-
(
sulted in nuclear export of GFP-Foxo4, which could be d
blocked by the PI3K-specific inhibitor LY294002. w
We next tested whether ectopically expressed Foxo4 (
icould inhibit SMC differentiation. Foxo4 contains three
vAkt phosphorylation sites (Thr32, Ser197, and Ser262)
that mediate nuclear export in response to IGF-I signal-
ing (Van Der Heide et al., 2004). Mutation of these three
sphosphorylation sites to Ala (GFP-Foxo4-TM) resulted
pin a constitutively nuclear localized Foxo4 protein that
swas refractory to IGF-I signaling (Figure 1A, bottom).
eUnder serum-free conditions, GFP-Foxo4-TM, as well
(as wild-type GFP-Foxo4, were nuclear localized in
tSMCs (Figure 1B, top). About 80% of the transfected
tcells showed reduced expression of SM differentiation
cmarkers, such as calponin, compared to nontrans-
sfected cells (Figure 1B, top, red staining, and Figure 1C)
For cells expressing GFP alone (data not shown). IGF-I
cpromoted nuclear export of wild-type GFP-Foxo4, and
ecells with cytoplasmic GFP-Foxo4 showed normal SM-
2calponin staining, whereas GFP-Foxo4-TM was resis-
Ftant to IGF-I signaling, and its nuclear localization and
inhibitory effect on SM calponin expression were undi-
minished by IGF-I (Figures 1B, bottom, and 1C). I
ITo rule out the possibility that the inhibitory effect
of Foxo4 on SMC differentiation was due to the high T
oexpression level resulting from transient transfection,
we stably transfected the A7r5 cells with a lentivirus b
avector (pLenti) alone and pLenti-Flag-Foxo4-TM, re-igure 1. PI3K/Akt Signaling Promotes SMC Differentiation through
nactivation of Foxo4
A) A7r5 SMCs cultured on microscope slides were transfected with
GFP-Foxo4 (top) and GFP-Foxo4-TM (bottom) expression vec-
ors, respectively. 24 hr later, cells were serum starved overnight,
t which time IGF-I was added in the presence or absence of
Y294002. 24 hr after IGF-I treatment, cells were washed, fixed,
nd mounted for microscopic analysis.
B) A7r5 cells were transiently transfected with expression vectors
ncoding GFP-Foxo4, GFP-Foxo4-TM, and GFP-Foxo4-TMN, cul-
ured under the conditions of serum free (top) and serum free plus
GF-I (bottom), and stained with antibody against the SM-specific
ifferentiation marker SM-calponin (red).
C) Quantification of number of cells stained with SM-calponin. Ten
ifferent fields containing transfected and nontransfected cells
ere randomly chosen and scored for SM-calponin staining.
D) Quantitative real-time PCR analysis of transcripts of SM genes
n A7r5 cells stably transfected with Flag-tagged Foxo4-TM and
ector alone (n = 3, mean ± SEM).pectively, and compared the mRNA levels of SM-cal-
onin and SM22α by quantitative real-time PCR analy-
is. After drug selection with Blastitin, A7r5 cells that
xpressed only low levels of Foxo4-TM were recovered
Figure 1D). We were unable to obtain clonal A7r5 cells
hat expressed high levels of Foxo4-TM. This is consis-
ent with the fact that Foxo proteins can induce cell-
ycle inhibitor p21 expression (Nakae et al., 2003). As
hown in Figure 1D, A7r5 cells stably transfected with
lag-Foxo4-TM displayed reduced expression of SM-
alponin and SM22α compared to control A7r5 cells,
ven though the Foxo4 level was increased by less than
-fold. Taken together, our data suggest that nuclear
oxo4 can inhibit SMC differentiation.
nhibition of Differentiation of SMCs by Foxo4
s Independent of DNA Binding
o determine whether the inhibitory effect of Foxo4-TM
n expression of SM differentiation markers requires its
inding to a Foxo-responsive element (FRE), we cre-
ted a mutant protein (Foxo4-TMN) in which Asn152 in
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Asn152 is highly conserved among forkhead transcrip-
tion factors and is in direct contact with DNA (Clark et
al., 1993; Weigelt et al., 2001). The mutation abolished
DNA binding to a canonical FRE sequence in a gel shift
assay (Figures 2A and 2B).
The influence of Foxo4-TMN on the responsiveness
of SMCs to PI3K/Akt signaling was explored by con-
structing a tetracycline (tet)-responsive recombinant
adenovirus (Adtet-off-Foxo4-TMN) in which expression
of Foxo4-TMN was repressed in the presence of doxy-
cyclin (Dox). In the presence of 10 ng/ml Dox, Foxo4-
TMN expression was repressed to an undetectable
level, whereas at a concentration of 0.1 ng/ml, Dox did
not significantly inhibit Foxo4-TMN expression (Figure
2C). A7r5 cells expressing Foxo4-TMN showed de-
creased expression of SM marker genes compared to
control A7r5 cells (Figure 2C). Dox had no effect on the
expression of SM markers in wild-type A7r5 cells (data
not shown).
We next investigated whether Foxo4-TMN could
override the promyogenic influence of PI3K/Akt signal-Figure 2. Nuclear Foxo4 Blocks PI3K/Akt-Mediated SMC Differenti-
ation Independently of DNA Binding
(A) A gel mobility shift assay was performed with a radiolabeled
Foxo4 binding site and extracts of COS cell transfected with the
indicated Foxo4 plasmids. The positions of DNA-protein com-
plexes and a nonspecific band are indicated.
(B) Western blot of COS cell extracts expressing the indicated Flag-
Foxo4 proteins used in (A).
(C) Western blot analysis of SM contractile proteins in A7r5 cells
infected with Adtet-off-Foxo4-TMN in the presence of 0.1 or 10 ng/
ml doxycyclin. After 4 days in culture, cell lysates were prepared
and analyzed by Western blot. α-tubulin was measured as a load-
ing control.
(D and E) The effects of Foxo4-TMN expression on signal-depen-
dent phosphorylation of Akt (D) and induction of SM calponin (E).
A7r5 cells were infected with Adtet-off-Foxo4-TMN in the presence
of 0.1 or 10 ng/ml doxycyclin. 16 hr after infection, the culture me-
dium was changed to serum-free medium. 24 hr after serum with-
drawal, IGF-I was added either alone or in combination with
LY294002 as indicated. Cells were harvested for (D) Western blot
and (E) quantitative real-time PCR analysis of transcript of SM cal-
ponin normalized against GAPDH (n = 3, mean ± SEM).ing. The inhibitory effect of GFP-Foxo4-TMN on SMC
differentiation was first tested by expressing GFP-
Foxo4-TMN in A7r5 SMCs (Figure 1B). Like wild-type
GFP-Foxo4 and GFP-Foxo4-TM, GFP-Foxo4-TMN in-
hibited the expression of SM-calponin when expressed
in the nucleus of A7r5 cells, and it was refractory to
IGF-I signaling (Figures 1B and 1C).
We then infected A7r5 cells with an adenovirus en-
coding Foxo4-TMN (Adtet-off-Foxo4-TMN) (Figures 2D
and 2E). Twenty-four hours after infection, cells were
serum starved and stimulated with IGF-I in the pres-
ence or absence of LY294002. Lysates were harvested
1 hr later for Western blot (Figure 2D) and 16 hr later
for real-time PCR (Figure 2E) analysis. Activation of the
PI3K/Akt pathway in the presence and absence of
nuclear Foxo4-TMN was measured by monitoring the
phosphorylation of Akt (Figure 2D). The effects of IGF-
I-activated PI3K/Akt signaling on SM gene expression
were measured by quantitative real-time PCR of SM-
calponin (Figure 2E). As shown in Figure 2D, IGF-I
activated the PI3K-Akt signaling pathway and led to
sustained phosphorylation of Akt as detected by an an-
tibody against phospho-threonine308. IGF-I-dependent
phosphorylation of Akt was similar in SMCs with and
without nuclear Foxo4-TMN (Figure 2D, lanes 2 and 5),
indicating that nuclear Foxo4-TMN does not affect acti-
vation of PI3K/Akt signaling. This is consistent with the
notion that Foxo4 acts downstream of Akt phosphory-
lation in the PI3K/Akt pathway.
SMCs express endogenous IGF-I (Liu et al., 2004).
Addition of exogenous IGF-I had little effect on SM
gene expression even though PI3K/Akt signaling is ele-
vated. However, SM-calponin is significantly decreased
below the basal level when PI3K/Akt signaling is inacti-
vated by LY294002 (Figure 2E), consistent with the no-
tion that PI3K/Akt pathway promotes SM differentia-
tion. Foxo4-TMN inhibits expression of SM-calponin
(Figure 2E). More importantly, the change of SM gene
expression upon activation of PI3K/Akt signaling in the
presence of nuclear Foxo4-TMN was significantly de-
creased compared to that of control cells (Figure 2E),
suggesting that nuclear Foxo4 could override the pro-
myogenic effect of activated PI3K/Akt signaling. These
results demonstrate that Foxo4 blocks SMC differentia-
tion and that the promyogenic effects of PI3K/Akt occur
through a mechanism independent of Foxo4 DNA
binding.
Foxo4 siRNA Promotes the Expression of SM
Contractile Genes
To further test the involvement of Foxo4 in modulation
of SMC phenotypes, we performed gene knockdown
experiments with Foxo4 siRNA. As shown in Figure 3A,
transfection of A7r5 cells with increasing amounts of
Foxo4 siRNA resulted in a pronounced increase in
expression of luciferase reporters controlled by the
SM22a, SM-a-actin, and SM-MHC promoters. The ef-
fects of Foxo4 siRNA on the promoters of these SM
contractile genes were specific, as Foxo4 siRNA had
little effect on an SV40-promoter-luciferase reporter.
Transfection with GFP siRNA as a control also had little
or no effect on SM gene-reporter activities.
Transfection of Foxo4-specific siRNA into A7r5 cells
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Figure 3. Inactivation of Foxo4 in A7r5 Cells by siRNA Upregulates C
the Expression of SM Markers t
(A) A7r5 cells were transfected with luciferase reporters controlled t
by the SV40, SM22a, SM-a-actin, and SM-MHC promoters, a CMV-
FlacZ expression plasmid as an internal control, and increasing
3amounts of GFP siRNA or Foxo4 siRNA (15, 30, and 60 nM), as
aindicated. Cells were harvested 72 hr after transfection and as-
sayed for luciferase and lacZ activities. Luciferase activities are ex- b
pressed relative to the level of expression with the reporter gene g
alone (n = 3, mean ± SEM). o
(B) Semiquantitative RT-PCR analysis of transcripts of three Foxo
pmRNAs and SMmarkers in A7r5 cells transfected with nonsilencing
bFITC-labeled scrambled siRNA (si-FITC) and Foxo4 siRNA. GAPDH
was used as an RNA loading control.
(C) Quantitative analysis of transcripts in A7r5 cells transfected F
with siRNA-FITC and Foxo4 siRNA by real-time PCR. mRNA tran- B
scripts in Foxo4 siRNA-transfected A7r5 cells were normalized to
ptranscripts in si-FITC-transfected A7r5 cells and expressed as %
tchange (n = 3, mean ± SEM).
h(D) Chromatin immunoprecipitation of Foxo4-promoter complexes.
In vivo crosslinked chromatin was prepared from A7r5 cells in- g
fected with Adtet-off-myc-Foxo4-TMN and immunoprecipitated W
with anti-myc or IgG antibody followed by PCR amplification using a
primer pairs specific for the SM-MLCK, SM22a, SM-a-actin, and
Fp21cip1 promoters. Input represents DNA extracts from chromatin
mprior to immunoprecipitation.
s(E) ChIP assay performed with anti-Foxo4 antibody and chromatin
lysates from SMCs A10. a
t
a
cresulted in nearly a complete loss of Foxo4 mRNA but
no change in Foxo1 and Foxo3a mRNA expression (Fig- S
sures 3B and 3C). The stimulatory effects of Foxo4
siRNA on smooth muscle promoters were accompa- t
dnied by increases in expression of transcripts encoding
the corresponding proteins, as measured by semiquan- d
otitative reverse transcriptase (RT) (Figure 3B) and quan-
titative real-time PCR (Figure 3C). m
(To investigate whether Foxo4 regulates SM differenti-
ation by associating with the promoters of SMC marker t
wgenes, we carried out chromatin immunoprecipitation
(ChIP) assays. Chromatin fragments from lysates of 5
cA7r5 cells infected with adenovirus expressing myc-oxo4-TMN were precipitated with anti-myc antibody
r control IgG (Figure 3D). DNA from the immunopreci-
itates was subjected to PCR analysis using primers
pecific to the promoter regions of the SM-MLCK, SM-
-actin, and SM22a genes and the p21cip1 gene, which
ncodes an inhibitor of the cell cycle (Sherr and Rob-
rts, 1999). As shown in Figure 3D, chromatin fragments
ontaining the SRF/myocardin binding site CArG-box in
he promoter regions of SM genes were specifically im-
unoprecipitated by anti-myc antibody in cells ex-
ressing myc-Foxo4-TMN. No chromatin fragments
ere precipitated from myc-Foxo4-TMN-expressing
ells by control IgG or by anti-myc antibody in the ab-
ence of myc-Foxo4-TMN. Chromatin corresponding to
xon 5 of the SM22a gene served as a negative control
or the specificity of Foxo4 binding to the SM22α
romoter. No chromatin fragment containing the Foxo-
esponsive element in the promoter region of the cell-
ycle inhibitor p21cip1 was precipitated in myc-Foxo4-
MN-expressing cells by anti-myc antibody, consistent
ith the inability of Foxo4-TMN to bind to a canonical
RE (Figure 2A).
To test whether the endogenous Foxo4 protein binds
o the promoters of SMC marker genes, we performed
hIP assays with anti-Foxo4 antibody and lysates of
he SMC line A10, as these cells showed more prolifera-
ive phenotypes and higher expression of endogenous
oxo4 proteins (data not shown). As shown in Figure
E, a chromatin fragment corresponding to the SM
-actin promoter was specifically immunoprecipitated
y anti-Foxo4 antibody, but not by control IgG, sug-
esting that endogenous Foxo4 binds to the promoter
f this SM marker gene. Contrary to ectopically ex-
ressed Foxo4-TMN, endogenous Foxo4 was found to
ind FRE in the p21 promoter region (Figure 3E).
oxo4 Interacts with Myocardin
ecause Foxo4 suppressed the activity of SMC gene
romoters and myocardin is sufficient and necessary
o activate SM gene expression (Wang et al., 2003b), we
ypothesized that the inhibitory effect of Foxo4 on SMC
ene expression might be mediated through myocardin.
e first tested if endogenous Foxo4 is physically associ-
ted with myocardin by coimmunoprecipitation with anti-
oxo4 antibody followed by immunobloting with anti-
yocardin antibody using lysates of A10 SMCs. As
hown in Figure 4A, myocardin was found to specific-
lly associate with endogenous Foxo4 in vivo. We fur-
her confirmed this interaction with epitope tag-specific
ntibodies and mapped the interactive domain by
oimmunoprecipitation and GST pull-down assays.
pecific interaction of myocardin and Foxo4 was ob-
erved in transfected COS cells by coimmunoprecipita-
ion (Figure 4B, lanes 1 and 2). The myocardin binding
omain of Foxo4 was mapped using a series of Foxo4
eletion mutants. Both an N-terminal deletion mutant
f Foxo4 (residues 89–505) and a C-terminal deletion
utant (residues 1–325) interacted with myocardin
lanes 5 and 4). The overlapping region of these dele-
ion mutants (residues 89–325) also strongly interacted
ith myocardin (lane 7). Foxo4(1–152) and Foxo4(325–
05) did not interact with myocardin (lanes 3 and 6). We
onclude that residues between 89 and 325 of Foxo4,
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265Figure 4. Interaction of Foxo4 with Myo-
cardin
(A) Cell lysates of A10 were immunoprecipi-
tated with anti-Foxo4 antibody or control
IgG, and the immunoprecipitates were sub-
jected to SDS-PAGE and immunoblotted
with anti-myocardin antibody.
(B) COS cells were transfected with expres-
sion vectors encoding myc-myocardin and
wild-type or deletion mutants of Flag-tagged
Foxo4. Cell lysates were incubated with anti-
Flag (Foxo4) antibody, and the immunopreci-
pitates were probed with anti-myc (myocar-
din) antibody by Western blot analysis. The
data shown correspond to a representative
experiment performed with all constructs in
parallel. No binding to the Foxo4(1–152) and
Foxo4(325–505) fragments was observed in
multiple independent experiments with higher
protein expression levels of myocardin (data
not shown).
(C) Schematic representation of deletion
constructs of Foxo4 used in (B).
(D) Mapping the interactive domain of myo-
cardin and Foxo4 by GST pull-down experi-
ments. Left: Aliquots of in vitro translated
35S-labeled full-length and deletion mutants
of myocardin were incubated with glutathi-
one-Sepharose beads loaded with bacteri-
ally expressed GST alone or GST-Foxo4
overnight at 4°C. The retained 35S-labeled
myocardin proteins were separated on SDS-
PAGE followed by autoradiography. 10% of
input is shown in the bottom panel. In con-
trol experiments, no binding of myocardin
proteins to the GST beads was observed
(not shown). Right: GST pull-down experi-
ments with bacterially expressed myocardin
(residues 129–510) and aliquots of in vitro
translated Foxo4 and Foxo4 mutants.
(E) Schematic representation of deletion
constructs of myocardin used in (D).
(F) Coimmunoprecipitation experiments with
lysates of COS cells transfected with plas-
mids as indicated.which includes the forkhead domain, are sufficient to
bind myocardin (Figure 4C).
To map the Foxo4 binding region of myocardin, we
carried out GST pull-down experiments using GST-
Foxo4 fusion proteins and myocardin deletion mutants
translated in vitro. As shown in Figure 4D (left), Foxo4
interacted efficiently with myocardin. A myocardin
N-terminal deletion mutant lacking residues 1–128 re-
tained the ability to interact with Foxo4 (lane 2), whereas
a mutant lacking the N-terminal 347 residues (amino
acids 348–935) did not interact (lane 3). Additional ex-
periments with C-terminal deletions localized the Foxo4
binding region of myocardin to residues 129–438, which
encompass the SRF binding region and SAP domain of
myocardin (Figure 4E). To further delineate the Foxo4
binding domain of myocardin, we tested the interac-
tions of several internal deletion mutants of myocardin
with GST-Foxo4. As shown in Figure 4D, deletion of the
glutamine-rich domain had little effect on myocardin
binding to Foxo4, whereas deletion of either the basic
domain or the SAP domain significantly reduced the
binding of myocardin to Foxo4. Taken together, these
data suggest that the basic and SAP domains are thekey regions required for Foxo4 binding. Using a GST-
myocardin fusion protein containing residues 129–510
and a series of Foxo4 deletion mutants translated in
vitro (Figure 4D, right), we confirmed that amino acid
residues 89–325 of Foxo4 interact directly with the 129–
510 fragment of myocardin.
Foxo4 Interacts with SRF
Because the Foxo4 binding domain of myocardin over-
laps with the SRF binding domain, we tested whether
Foxo4 competes with SRF for binding to myocardin.
We carried out coimmunoprecipitation experiments of
Foxo4 and myocardin in the presence and absence of
SRF. As shown in Figure 4F, Foxo4 interacts with myo-
cardin and this interaction is enhanced in the presence
of SRF (Figure 4F, lanes 2 and 3). Similar coimmuno-
precipitation experiments showed that Foxo4 interacts
with SRF and the interaction is increased in the pres-
ence of myocardin (Figure 4F, lanes 5 and 6). Taken to-
gether, our data suggest that Foxo4 forms a ternary
complex with myocardin and SRF and that there may
be some cooperativity between the binary interactions
to yield the ternary complex.
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mActivity of Myocardin
To test whether Foxo4 interferes with the transcriptional t
factivity of myocardin, we performed a promoter-repor-
ter assay using myocardin and various deletion mu- c
αtants of Foxo4. Foxo4 had no effect on myocardin ex-
pression (Figure 4B, lanes 1 and 2) but inhibited the p
ttranscriptional activity of myocardin in a dose-depen-
dent manner (Figure 5A). The Foxo4 mutant Foxo4- g
cTMN, which is constitutively nuclear and DNA binding
defective, showed similar dose-dependent inhibition of c
(the transcriptional activity of myocardin (Figure 5A,
compare lanes 8–11). b
(To determine whether inhibition of the transcriptional
activity of myocardin by Foxo4 correlated with its bind- i
aing to myocardin, we examined the effects of the
Foxo4(89–325) deletion mutant on myocardin’s tran- g
scriptional activity. As shown in Figure 5A, Foxo4(89–
325), which bound myocardin strongly in both GST pull- F
odown and coimmunoprecipitation experiments, had a
similar dose-dependent inhibitory effect on the tran- T
Fscriptional activity of myocardin as wild-type Foxo4
(Figure 5A, lanes 13–16). w
iTo determine whether the inhibitory effect of Foxo4
on the transcriptional activity of myocardin was specific a
eto Foxo4, we tested whether Foxo1 and Foxo3a were
able to block the stimulatory effect of myocardin on the 1
rSM22 promoter. The expression of Foxo1 and Foxo3a
was confirmed by Western blot analysis (Figure 5B). In- n
aterestingly, we found that Foxo1 and Foxo3a were un-
able to repress the transcriptional activity of myocardin t
(Figure 5A, lanes 18–21 and 23–26).
10T1/2 cells expressing myocardin adopt morpholo- D
gies reminiscent of differentiated myocytes and ex-
press a set of SM gene markers when cultured in me- T
tdium lacking serum (Wang et al., 2003b). To examineFigure 5. Foxo4 Inhibits the Transcriptional
and Myogenic Activity of Myocardin
(A) COS cells were transfected with a myo-
cardin expression vector (0.2 g), a lucifer-
ase reporter controlled by the SM22α pro-
moter, a CMV-lacZ expression plasmid as an
internal control, and increasing amounts of
DNA constructs (0.1, 0.2, 0.4, and 0.8 g) ex-
pressing Foxo4, Foxo4-TMN, Foxo4(89–325),
Foxo1, and Foxo3a. Cells were harvested 24
hr later for measurement of luciferase and
lacZ activities. Luciferase activities in light
units were normalized to lacZ activities and
expressed as percentage of the luciferase
light units from cells transfected with myo-
cardin alone (n = 3, mean ± SEM).
(B) Western blot of Foxo proteins from the
lysates of COS cells transfected with equiva-
lent amounts of plasmids.
(C) 10T1/2 fibroblasts were transfected with
wild-type and mutants of Foxo4 and myo-
cardin in the absence or presence of wild-
type and mutant forms of Foxo4. 48 hr after
transfection, the culture medium was changed
to differentiation medium containing 2%
horse serum. Cells were harvested 2 days
later for RT-PCR analysis of transcripts of
SM contractile gene markers. GAPDH was
used as a control for RNA loading.hether Foxo4 suppresses the promyogenic activity of
yocardin, we assayed the effect of Foxo4 and dele-
ion mutants of Foxo4 on myocardin activity in trans-
ected 10T1/2 fibroblasts. As shown in Figure 5C, myo-
ardin induced the expression of the SM markers SM
-actin, SM22α, SM-MHC, SM-MLCK, and SM-cal-
onin (lane 2). Foxo4 and Foxo4-TMN strongly blocked
he ability of myocardin to activate the SM gene pro-
ram (lanes 8 and 9). Foxo4(89–325), which binds myo-
ardin and inhibits its transcriptional activity, also effi-
iently blocked the myogenic activity of myocardin
lane 10), whereas Foxo4(325–505), which does not
ind to myocardin, failed to interfere with its activity
lane 12). Thus, there is a direct correlation between the
nteraction of Foxo4 deletion mutants with myocardin
nd their ability to inhibit the transcriptional and myo-
enic activities of myocardin.
oxo4 Is Upregulated in Proliferating SMCs
f the Injured Neointima
o examine the possible involvement of endogenous
oxo4 in the modulation of SMC phenotypes in vivo,
e performed immunohistochemical staining for Foxo4
n SMCs of the neointimal layer of the mouse carotid
rtery following flow cessation injury (Figure 6A), a well-
stablished model of vascular injury (Kumar and Linder,
997). Four weeks after ligation of the left common ca-
otid artery, a neointimal lesion was clearly visible and
uclear Foxo4 was substantially upregulated in prolifer-
ting neointimal SMCs of the ligated artery but not in
he control uninjured artery (Figure 6B).
iscussion
he phenotypes of SMCs are highly plastic and sensi-
ive to extracellular cues. In response to insulin and
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267Figure 6. Foxo4 Is Upregulated in SMCs of
the Neointima in Ligated Carotid Artery of
Mice
(A) The left common carotid artery (LCCA)
was ligated distal to the aortic arch near the
bifurcation.
(B–D) 28 days after ligation, both right and
left common carotid arteries were harvested,
fixed, sectioned, and stained with anti-
Foxo4 antibody. No specific Foxo4 staining
was observed in the ligated carotid artery
when primary antibody was omitted in the
immunohistochemistry (data not shown).
RCCA, right common carotid artery; LCCA,
left common carotid artery; AA, aortic arch.IGF-I, SMCs adopt a differentiated phenotype. Con-
versely, various mitogenic signals or injury, for instance
to a blood vessel wall, result in dedifferentiation and
enhanced proliferation of SMCs. SRF plays a key role
in the control of SMC phenotypes as a consequence of
its association with differentiation-promoting cofactors
such as myocardin and its responsiveness to growth
factor signals (reviewed in Wang and Olson, 2004).
The results of this study indicate that Foxo4 serves
as a link between the PI3K/Akt signaling pathway and
myocardin, a key transcriptional activator of the SM dif-
ferentiation program. The following observations support
this conclusion. (1) The PI3K/Akt signaling pathway inac-
tivates Foxo4 and promotes SMC differentiation. (2) Over-
expression of a signal-resistant Foxo4 mutant protein
represses the expression of SM differentiation mark-
ers and blocks PI3K/Akt-induced SMC differentiation,
whereas reduction of Foxo4 expression by siRNA en-
hances SM differentiation. (3) Foxo4 is associated with
chromatin on the promoters of SM genes and physi-
cally associates with myocardin. (4) Foxo4 represses
the ability of myocardin to activate expression of en-
dogenous SM genes, as well as reporter genes con-
trolled by SM gene promoters. (5) There is a direct cor-
relation between the domains of Foxo4 required for
interaction with myocardin and repression of SM gene
expression.
Based on these results, we propose a mechanistic
model of SMC phenotypic modulation by IGF-I (Figure
7). In the absence of IGF signaling, Foxo4 binds myo-
cardin in the nucleus and represses its myogenic activ-
ity. IGF-I activates the PI3K-Akt pathway, which leads
to phosphorylation of Foxo4. Phosphorylated Foxo4
translocates to the cytoplasm, releasing myocardin
from its repressive influence and allowing activation of
myocardin-dependent genes and SM differentiation.
Opposition between the Ras-MAPK and PI3K-Akt
Pathways during Phenotypic Modulation of SMCs
The Ras-MAPK and PI3K-Akt pathways have been
shown to modulate SMC phenotypes (Duan et al., 2000;
Hayashi et al., 1999; Wang et al., 2003a, 2004). Insulin,
IGF-I, and PDGF can activate both pathways to dif-
ferent degrees. PI3K/Akt has been shown to promote
both proliferation and, paradoxically, differentiation of
SMCs (Hayashi et al., 1998; Duan et al., 2000). The netget of MAPK signaling (Wang et al., 2004). Hayashi et al.
Figure 7. A Model of SMC Phenotypic Modulation by the PI3K-Akt
and MAPK Pathways
Signaling by Insulin/IGF-I and PDGF preferentially activates the
PI3K/Akt and MEK/ERK pathways, respectively, although there can
be crosstalk between these pathways (indicated by dashed lines).
Akt phosphorylates Foxo4, which represses its activity by promot-
ing nuclear export, thereby relieving myocardin of the repressive
influence of Foxo4 and favoring activation of SM differentiation
genes. This pathway is antagonized by ERK phosphorylation of Elk,
which competes with myocardin for interaction with SRF, thereby
repressing SM differentiation.effect of the PI3K/Akt signaling pathway on SMC phe-
notypes is likely to depend on the nature of the growth
factors and the strength of the stimuli, as well as the
balance between the PI3K/Akt and Ras-MAPK path-
ways. In general, the Ras-MAPK pathway mediates the
proliferative and migratory effects of these growth fac-
tors (Duan et al., 2000; Hayashi et al., 1999; Wang et
al., 2003a, 2004), whereas the PI3K-Akt pathway is re-
quired for induction and maintenance of the differenti-
ated state of SMCs (Hayashi et al., 1998; Wang et al.,
2003a). We showed previously that PDGF represses
SMC genes through a MAPK pathway by displacing
myocardin from SRF with phosphorylated Elk-1, a tar-
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sthrough the PI3K/Akt pathway in primary SMCs cul-
tured on laminin-coated plates (Hayashi et al., 1998). p
oWe observed little effect of IGF-I on SMC gene expres-
sion when added to serum-starved A7r5 cells (Figure t
2E), even in the presence of elevated PI3K/Akt signal-
ing. This could be due to a difference between primary q
pand immortalized cell lines. IGF-I may lose its potency
to preferentially activate the PI3K/Akt pathway that pro- t
mmotes SM differentiation in immortalized cells. How-
ever, we did observe that IGF-I overrides the inhibitory t
teffect of ectopically expressed Foxo4 on the differenti-
ation of SMCs (Figure 1), and constitutively nuclear m
tFoxo4 is refractory to activated PI3K/Akt signaling.
Based on these observations, we propose that IGF-I w
rpromotes expression of SMC differentiation markers, at
least in part, through the PI3K/Akt pathway by relieving G
Fmyocardin of the inhibitory influence of Foxo4 (Fig-
ure 7). l
p
rCellular Functions of Foxo Proteins
Foxo proteins are shared components among path-
ways regulating diverse cellular functions including M
proliferation, differentiation, metabolism, and survival V
(Accili and Arden, 2004). Foxo proteins have been I
shown to induce cell-cycle arrest and apoptosis and to t
promote long-term survival of quiescent cells. In addi- p
tion, overexpression of Foxo proteins inhibits differenti- w
ation of adipocytes (Nakae et al., 2003), thymocytes c
(Leenders et al., 2000), and myoblasts (Bois and Gros- t
veld, 2003; Hribal et al., 2003). Our results demonstrate s
that Foxo4 also inhibits differentiation of SMCs. p
The DNA binding activity of Foxo1 appears to be re- c
quired to inhibit the differentiation of both skeletal mus- t
cle and adipocytes (Nakae et al., 2003; Hribal et al., t
2003). The mechanism by which Foxo4 inhibits differen- t
tiation of SMCs does not require Foxo4 DNA binding t
activity or its transactivation domain and is therefore d
distinct from that of Foxo1. Consistent with this conclu- s
sion, a mutant form of Foxo4 unable to bind DNA spe- C
cifically associates with the promoter regions of SM dif- (
ferentiation markers, inhibits their expression, and blocks F
the myogenic activity of myocardin. Furthermore, unlike F
Foxo4, Foxo1 was unable to inhibit the transcriptional t
activity of myocardin, suggesting that the DNA binding c
activity of Foxo proteins, which is conserved among the t
Foxo family members, is not involved in inhibition of s
SMC differentiation. These results indicate that the in- c
hibitory effect of Foxo4 on SMC differentiation is unique c
and specific. z
d
sMechanisms of Regulation of the Transcriptional
Activity of Myocardin by Foxo4 f
dThere are several mechanisms by which Foxo4 might
regulate the transcriptional activity of myocardin. Foxo4 r
(could potentially displace myocardin from SRF, as we
showed previously for Elk-1 (Wang et al., 2004). We p
ghave tested this possibility by titrating Foxo4 into a gel
shift assay with myocardin and SRF but saw no diminu- m
ttion of the myocardin/SRF complex. We were also un-
able to detect a quaternary complex of SRF/myocardin/
FFoxo4/DNA in this assay, possibly because such a
complex cannot withstand the conditions of the gel chift assay. Nevertheless, in coimmunoprecipitation as-
ays, the amount of myocardin (or SRF) coimmuno-
recipitated with Foxo4 is increased in the presence
f SRF (or myocardin), suggesting that Foxo4 forms a
ernary complex with myocardin and SRF.
Both basic and SAP domains of myocardin are re-
uired for Foxo4 binding. The SAP domain plays an im-
ortant role in chromatin remodeling, thus influencing
ranscription (Wang et al., 2001). Binding of Foxo4 and
yocardin may interfere with the interaction between
he SAP domain and chromatin and thereby inhibit the
ranscriptional activity of myocardin. Alternatively, Foxo4
ay recruit conventional corepressor(s) such as HDACs
o the transcriptional complex. Recently, Foxo proteins
ere shown to interact with class III HDACs (Sirt) and
egulate the expression of target genes (for review, see
iannakou and Partridge, 2004). We have found that
oxo4 interacts with HDAC4 (Z.-P.L. and E.N.O., unpub-
ished results). Whether Foxo4 recruits HDAC4 to re-
ress the transcriptional activity of myocardin in vivo
emains to be determined.
odulation of SMC Phenotypes in the Blood
essel Wall by Foxo4
n response to injury, the SMCs in the media layer of
he blood vessel wall are triggered to dedifferentiate,
roliferate, and migrate to the intimal layer of the vessel
all, with consequent formation of neointima and vas-
ular occlusion. This form of SMC phenotypic modula-
ion is especially robust in atherosclerosis and vascular
tenosis following angioplasty (Owens et al., 2004). The
henotypic modulation of SMCs involves four major
ellular processes: proliferation, migration, differentia-
ion, and apoptosis. The underlying mechanisms for
hese processes are complex and may be at least par-
ially independent of each other. It has been shown that
he expression of SM marker genes is dramatically
ownregulated in response to injury and that suppres-
ion of SM gene expression in vivo depends on the
ArG box sequence and activities of SRF/myocardin
Hendrix et al., 2005). In this study, we have shown that
oxo4 inhibits SMC differentiation and that nuclear
oxo4 is upregulated in proliferating SMCs of neoin-
ima. In light of the dedifferentiation of SMCs that ac-
ompanies neointima formation in response to injury,
he upregulation of Foxo4 expression in these cells
uggests that the mechanism we have uncovered in
ultured SMCs might also be operative in vivo under
onditions of SMC phenotypic modulation. Mice homo-
ygous for a Foxo4 null allele are viable and do not
isplay overt abnormalities (Hosaka et al., 2004). When
ubjected to carotid artery ligation, a potent stimulus
or phenotypic modulation for SMCs, Foxo4 null mice
isplay impaired neointima formation, in contrast to the
obust growth of the neointima in wild-type mice
Z.-P.L., E.N.O., D.H. Castrillon, and R.A. Depinho, un-
ublished results). Taken together, these results sug-
est an important requirement for Foxo4 in vascular re-
odeling following injury to the vessel wall, a process
hat requires suppression of SM gene expression.
It has been shown recently that overexpression of
oxo3a (FKHRL1) in SMCs of rat carotid artery de-
reases neointimal SMC hyperplasia following balloon
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269injury (Park et al., 2005). A potential mechanism is that
Foxo3a induces SMC apoptosis and upregulates the
cell-cycle inhibitor p27, which results in smooth muscle
cell-cycle arrest. These findings do not necessarily
contradict our results. It is possible that different Foxo
proteins are involved in different aspects of phenotypic
modulation and operate independently. Consistent with
this possibility, we have shown that Foxo1 and Foxo3a,
unlike Foxo4, do not inhibit myocardin-mediated tran-
scriptional activation, and the inhibitory effect of Foxo4
on SMC differentiation does not require its DNA bind-
ing activity.
In summary, our studies suggest that upregulation of
Foxo4 is critical for the phenotypic modulation of SMCs
that occurs upon vascular injury, triggering dedifferenti-
ation of SMCs through repression of myocardin-medi-
ated activation of SM differentiation genes. As pheno-
typic modulation of SMCs involves other cellular events
such as proliferation, migration, and apoptosis, it will
be important to investigate whether Foxo4 plays a role
in these events and to study the mechanisms of cou-
pling between these processes.
Experimental Procedures
Plasmids
A mouse cDNA of Foxo4 in the pBluescript vector was a kind gift
from Dr. K. Arden. The mammalian expression vectors of Foxo4
and various deletion mutants were constructed by subcloning poly-
merase chain reaction (PCR)-amplified inserts into pcDNA3-Flag,
pcDNA3-myc, and pEGFP. GST-Foxo4 was constructed by sub-
cloning the PCR-amplified full-length Foxo4 coding sequence into
the EcoR1 and Xho1 sites of the pGEX-KG vector. GST-myocar-
din(129–510), Sm22α-luciferase, Flag- and myc-tagged myocardin,
and various deletion mutants of myocardin were described pre-
viously (Wang et al., 2001). SM-α-actin-luciferase and SM-MHC-
luciferase plasmids were kind gifts from Dr. G.K. Owens. Site-
directed mutagenesis was performed using the quick-change
mutagenesis kit (Stratagene). More detailed information about the
plasmids used in this paper is available upon request.
Adenovirus Production
Recombinant Tet-off adenovirus containing myc-Foxo4-TMN was
constructed according to the manufacturer’s protocol (Adeno-X
Tet-Off expression system, Clontech). Cells were infected with ade-
novirus (Adtet-off-Foxo4-TMN and Adtet-off) at a total moi of 5
plaque-forming units/cell. The ratio of the two adenoviruses Adtet-
off-Foxo4-TMN and Ad-Tet-Off was 1:4. The expression level of
myc-Foxo4-TMN was controlled by addition of doxycyclin to the
culture medium.
RNA Analysis
Total RNA was isolated with Trizol reagent (Invitrogen) according to
the manufacturer’s protocol. After treatment with DNase I (DNA
free, Ambion), random hexamer primed single-strand cDNAs were
synthesized from 2 g of total RNA using SuperscriptIII (Invitrogen).
The sequences of the primer sets for PCR are available upon re-
quest.
Real-time PCR was performed using TaqMan on an ABI-PE Prism
7000 sequence detection system (Applied Biosystems) according
to the protocol provided by the manufacturer. The primers and
probe sequences are available upon request. The relative quanti-
ties of mRNA were determined using either standard curve or com-
parative CT method and normalized against GAPDH mRNA.
Cell Culture, Transfection, and Luciferase Assays
10T1/2 (ATCC), rat aortic smooth muscle cells A7r5 and A10
(ATCC), and COS cells were maintained in DMEM supplemented
with 10% FBS, 2 mM glutamine, and 100 U/ml penicillin/streptomy-
ocin (Invitrogen). For experiments under serum-free conditions,A7r5 cells were cultured in 1:1 DMEM/Ham’s F-12 mixture (Invitro-
gen) supplemented with 6.25 ng/ml sodium selenite, 5 mg/ml
transferrin, and 0.2 mM L-ascorbic acid.
COS cells were transfected using Fugene 6 reagent according to
manufacturer’s instructions (Roche). 10T1/2 and A7r5 cells were
transfected with lipofectamine-plus in serum-free medium as indi-
cated by the manufacturer (Invitrogen). After transfection, cells
were cultured as described for each experiment. Cell extracts were
assayed for luciferase expression using the luciferase assay kit
(Promega). Relative promoter activities are expressed as lumines-
cence relative units normalized for β-galactosidase expression in
the cell extracts.
For stable transfection, A7r5 cells were transfected with plenti6-
TOPO-Flag-Foxo4-TM or plenty-6-TOPO using lipofectamine plus
transfection kit (Invitrogen). Cells were selected with Blasticidin (10
g/ml) for 2 weeks.
Chromatin Immunoprecipitation, Immunoprecipitation,
and Western Blotting
Chromatin immunoprecipitation (ChIP) assays were carried out
using the ChIP Assay Kit from Upstate Biotech following the manu-
facturer’s protocol. Primer sequence for SM22a, SM-MLCK, SM-a-
actin, and p21cip1 are available upon request.
Cells were lysed with a PBSTxE buffer (phosphate-buffered sa-
line, 0.5% Triton-X 100, and 1 mM EDTA) containing 1× protease
inhibitor cocktails (Roche). The cell lysates were incubated over-
night at 4°C with Flag-antibody (M2) conjugated to agarose beads
(Sigma) or suitable antibodies and protein A/G plus beads as indi-
cated in the experiments. The beads were washed three times in
lysis buffer. Immunoprecipitates were subjected to SDS-PAGE and
probed with appropriate antibodies as indicated in the experi-
ments. Western blotting was performed according to standard pro-
tocols.
GST Pull-Down Assays
GST, GST-Foxo4, GST-myocardin(129–510), GST-MITR(183–284),
and GST-HDAC4(208–310) were prepared as described previously
(Wang et al., 2001), except that the fusion proteins were not eluted.
Flag-Foxo4, Flag-myocardin, HDACs, MITR, and various deletion
mutants of Foxo4, myocardin, and MITR were translated in vitro
and labeled with 35S-methionine using the TNT T7-coupled reticu-
locyte lysate system following the manufacturer’s recommenda-
tions (Promega). The programmed lysates (10 l) were incubated
with 10 l GST or GST-fusion beads in 250 l PBSTxE buffer over-
night at 4°C. The beads were washed three times in PBSTxE buffer
and mixed with 1 volume of 2× SDS loading buffer, and bound pro-
teins were analyzed by SDS-PAGE using standard procedures.
Gel Shift Assays
The probe containing the IGFBP-1 IRS sequence (Tang et al., 1999;
lower case, 5#-GGcactagcaaaacaaacttatttgaacac-3#) was prepared
by Klenow-fill in with 32P-dCTP. The gel shift assay was carried out
as described previously (Wang et al., 2001).
Immunofluorescence
Cells were cultured on microscope slides. Twenty-four hours after
transfection, cells were washed twice in PBS and fixed in 4% para-
formaldehyde. The slides were mounted in vector shield medium
containing DAPI or stained with suitable antibodies indicated in the
experiments before mounting.
siRNA
The Foxo4-specific siRNA sequence was 5#-GGACAAGGGTGAC
AGCAACtt-3#. siRNA was transfected into A7r5 cells using lipofec-
tamine-plus reagent (Invitrogen). GFP siRNA and FITC-labeled non-
silencing duplex siRNA (si-FITC) (Qiagen) were used as negative
controls.
Carotid Artery Ligation and Immunohistochemistry
Male mice (8–10 weeks old) were used in accordance with the
guidelines of the National Institutes of Health and American Heart
Association for the care and use of laboratory animals. The pro-
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270cedure in this study was approved by the University of Texas (
FSouthwestern Medical Center Animal Care Committee.
Carotid artery was performed as described previously (Kumar H
and Linder, 1997). On postoperative day 28, the left and right ca- J
rotid arteries were harvested, fixed in 4% paraformaldehyde at 4°C p
overnight, and embedded transversely in paraffin. The immuno- C
histochemistry was performed using anti-Foxo4 antibody (1:100, K
Santa Cruz) following standard protocol. t
r
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